Pharmafile Logo

Another spellbinding result for Lucid Group at the 2018 PMEAs

November 23, 2018 |  

- PMLiVE
Lucid’s pioneering approach to medical education was clear to see as they scooped two top awards and a high commendation at last night’s awards ceremony.

The first award was gained in the category,
Excellence in Rare Diseases and Orphan Drugs’ for, Revolutionising Management of Hidradenitis Suppurativa in Europe: Why? What? How? This was coupled with a high commendation in the same category for, Advancing Science in a Rare Disease – A Cost Effective Clinical Decision Support Programme for Cystinosis.  

Lucid’s second big win of the night was being crowned PMEA Support Agency of the Year 2018, testament to the amazing client partnerships they have built over the last eleven years.

Jan Steele, Lucid COO and Co-founder commented, “I am delighted that the work of our teams and clients have been recognised. Our shared passion to make a difference and improve patients’ lives drives everything we do and underpins the magical programmes we create with our clients.” 

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD